| Attribute |
Value |
| 52 Week Change |
0.8213836 |
| Address1 |
7 Golda Meir Street |
| Address2 |
Weizmann Science Park |
| All Time High |
210.0 |
| All Time Low |
3.34 |
| Ask |
72.86 |
| Ask Size |
2 |
| Average Analyst Rating |
1.0 - Strong Buy |
| Average Daily Volume10 Day |
35,310 |
| Average Daily Volume3 Month |
55,287 |
| Average Volume |
55,287 |
| Average Volume10Days |
35,310 |
| Beta |
1.15 |
| Bid |
71.13 |
| Bid Size |
2 |
| Book Value |
14.69 |
| City |
Ness Ziona |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
Israel |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
68.3 |
| Current Ratio |
10.368 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,790,726,400 |
| Day High |
72.805 |
| Day Low |
68.3 |
| Debt To Equity |
1.601 |
| Display Name |
Sol-Gel |
| Dividend Yield |
0.0 |
| Earnings Timestamp |
1,787,229,000 |
| Earnings Timestamp End |
1,795,091,400 |
| Earnings Timestamp Start |
1,795,091,400 |
| Ebitda |
-17,690,000 |
| Ebitda Margins |
0.0 |
| Enterprise To Ebitda |
-9.975 |
| Enterprise To Revenue |
98.304 |
| Enterprise Value |
176,455,136 |
| Eps Current Year |
-8.73 |
| Eps Forward |
-8.35667 |
| Eps Trailing Twelve Months |
-5.61 |
| Esg Populated |
0 |
| Exchange |
NCM |
| Exchange Data Delayed By |
15 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
73.1283 |
| Fifty Day Average Change |
-4.8283005 |
| Fifty Day Average Change Percent |
-0.066025056 |
| Fifty Two Week Change Percent |
82.13836 |
| Fifty Two Week High |
97.97 |
| Fifty Two Week High Change |
-29.669998 |
| Fifty Two Week High Change Percent |
-0.3028478 |
| Fifty Two Week Low |
28.81 |
| Fifty Two Week Low Change |
39.490005 |
| Fifty Two Week Low Change Percent |
1.3707049 |
| Fifty Two Week Range |
28.81 - 97.97 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,517,495,400,000 |
| Float Shares |
489,004 |
| Forward Eps |
-8.35667 |
| Forward P E |
-8.173112 |
| Free Cashflow |
-2,120,250 |
| Full Exchange Name |
NasdaqCM |
| Full Time Employees |
28 |
| Fullday Change |
-4.0999985 |
| Fullday Change Percent |
-5.59574 |
| Fullday Price |
68.3 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.0 |
| Gross Profits |
-14,025,000 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.59657 |
| Held Percent Institutions |
0.43058 |
| Implied Shares Outstanding |
3,273,999 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,746,403,200 |
| Last Split Factor |
1:10 |
| Long Business Summary |
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel. |
| Long Name |
Sol-Gel Technologies Ltd. |
| Market |
us_market |
| Market Cap |
223,614,144 |
| Market State |
POSTPOST |
| Max Age |
86,400 |
| Message Board Id |
finmb_621569 |
| Most Recent Quarter |
1,782,777,600 |
| Net Income To Common |
-16,337,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
197,356,659 |
| Number Of Analyst Opinions |
2 |
| Open |
72.805 |
| Operating Cashflow |
-8,542,000 |
| Operating Margins |
-7.0422997 |
| Payout Ratio |
0.0 |
| Phone |
972 8 931 3433 |
| Previous Close |
72.4 |
| Price Eps Current Year |
-7.8235974 |
| Price Hint |
2 |
| Price To Book |
4.6494217 |
| Price To Sales Trailing12 Months |
124.576126 |
| Profit Margins |
0.0 |
| Quick Ratio |
9.873 |
| Quote Source Name |
Delayed Quote |
| Quote Type |
EQUITY |
| Recommendation Key |
strong_buy |
| Recommendation Mean |
1.0 |
| Region |
US |
| Regular Market Change |
-4.1 |
| Regular Market Change Percent |
-5.66298 |
| Regular Market Day High |
72.805 |
| Regular Market Day Low |
68.3 |
| Regular Market Day Range |
68.3 - 72.805 |
| Regular Market Open |
72.805 |
| Regular Market Previous Close |
72.4 |
| Regular Market Price |
68.3 |
| Regular Market Time |
1,791,921,600 |
| Regular Market Volume |
33,736 |
| Return On Assets |
-0.23868 |
| Return On Equity |
-0.40854 |
| Revenue Growth |
-0.966 |
| Revenue Per Share |
0.615 |
| Sand P52 Week Change |
0.17502642 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
3,273,999 |
| Shares Percent Shares Out |
0.044499997 |
| Shares Short |
145,819 |
| Shares Short Previous Month Date |
1,788,134,400 |
| Shares Short Prior Month |
74,053 |
| Short Name |
Sol-Gel Technologies Ltd. |
| Short Percent Of Float |
0.1378 |
| Short Ratio |
2.55 |
| Source Interval |
15 |
| Symbol |
SLGL |
| Target High Price |
195.0 |
| Target Low Price |
110.0 |
| Target Mean Price |
152.5 |
| Target Median Price |
152.5 |
| Total Cash |
47,929,000 |
| Total Cash Per Share |
14.639 |
| Total Debt |
770,000 |
| Total Revenue |
1,795,000 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-5.61 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
72.83364 |
| Two Hundred Day Average Change |
-4.533638 |
| Two Hundred Day Average Change Percent |
-0.062246483 |
| Type Disp |
Equity |
| Volume |
33,736 |
| Website |
https://www.sol-gel.com |
| Zip |
7,403,650 |